Considering OS (Fig. 7), patients benefited from RT were in the luminal A (p < 0.0001), luminal B/HER2-negative breast cancer (p < 0.0001), Basal-like (p = 0.0003), and HER2-enriched breast cancer groups (p = 0.02). This evidence concerns the gene ERBB2 and breast carcinoma.